ArticleBMJ open2021
Development of National Cancer Database for Cost and Quality of Life (CaDCQoL) in India: a protocol.
Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- A Mixed-Methods Assessment of India's Health Technology Assessment Ecosystem.Applied health economics and health policy · 2026Article
- Cancer-specific thresholds of treatment initiation delay and assessment of their confounding variables: authors' reply.The Lancet regional health. Southeast Asia · 2025Article
- Access to timely cancer treatment initiation in India: extent, determinants and trends.The Lancet regional health. Southeast Asia · 2025Article
- Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India.Applied health economics and health policy · 2024Article
- Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database.Health and quality of life outcomes · 2024Article
- Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India.JCO global oncology · 2024Article
- Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase- and ROS1 Fusion-Positive Non-Small Cell Lung Cancer in India.JCO global oncology · 2024Article
- Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment.The Lancet regional health. Southeast Asia · 2023Review
- Cost-effectiveness of population-based screening for oral cancer in India: an economic modelling study.The Lancet regional health. Southeast Asia · 2023Article
- Cost-effectiveness analysis of different combination therapies for the treatment of chronic lymphocytic leukaemia in India.The Lancet regional health. Southeast Asia · 2023Article
- Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India.JCO global oncology · 2023Article
- Financial toxicity of cancer treatment in India: towards closing the cancer care gap.Frontiers in public health · 2023Article
- Cost-effectiveness of Post-Mastectomy Radiotherapy (PMRT) for breast cancer in India: An economic modelling study.The Lancet regional health. Southeast Asia · 2022Article
- Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.Applied health economics and health policy · 2022Article
- Cost Effectiveness of Bevacizumab Plus Chemotherapy for the Treatment of Advanced and Metastatic Cervical Cancer in India-A Model-Based Economic Analysis.JCO global oncology · 2022Article
- Comprehensive value-based cancer care in India: Opportunities for systems strengthening.The Indian journal of medical research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rising economic burden of cancer on healthcare system and patients in India has led to the increased demand for evidence in order to inform policy decisions such as drug price regulation, setting reimbursement package rates under publicly financed health insurance schemes and prioritising available resources to maximise value of investments in health. Economic evaluations are an integral component of this important evidence. Lack of existing evidence on healthcare costs and health-related quality of life (HRQOL) makes conducting economic evaluations a very challenging task. Therefore, it is imperative to develop a national database for health expenditure and HRQOL for cancer. METHODS AND ANALYSIS: The present study proposes to develop a National Cancer Database for Cost and Quality of Life (CaDCQoL) in India. The healthcare costs will be estimated using a patient perspective. A cross-sectional study will be conducted to assess the direct out-of-pocket expenditure (OOPE), indirect cost and HRQOL among cancer patients who will be recruited at seven leading cancer centres from six states in India. Mean OOPE and HRQOL scores will be estimated by cancer site, stage of disease and type of treatment. Economic impact of cancer care on household financial risk protection will be assessed by estimating prevalence of catastrophic health expenditures and impoverishment. The national database would serve as a unique open access data repository to derive estimates of cancer-related OOPE and HRQOL. These estimates would be useful in conducting future cost-effectiveness analyses of management strategies for value-based cancer care. ETHICS AND DISSEMINATION: Approval was granted by Institutional Ethics Committee vide letter no. PGI/IEC-03/2020-1565 of Post Graduate Institute of Medical Education and Research, Chandigarh, India. The study results will be published in peer-reviewed journals and presented to the policymakers at national level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.